Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study. / Heftdal, Line Dam; Pérez-Alós, Laura; Hasselbalch, Rasmus Bo; Hansen, Cecilie Bo; Hamm, Sebastian Rask; Møller, Dina Leth; Pries-Heje, Mia; Fogh, Kamille; Gerstoft, Jan; Grønbæk, Kirsten; Ostrowski, Sisse Rye; Frikke-Schmidt, Ruth; Sørensen, Erik; Hilsted, Linda; Bundgaard, Henning; Garred, Peter; Iversen, Kasper; Sabin, Caroline; Nielsen, Susanne Dam.
In: EBioMedicine, Vol. 93, 104661, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
AU - Heftdal, Line Dam
AU - Pérez-Alós, Laura
AU - Hasselbalch, Rasmus Bo
AU - Hansen, Cecilie Bo
AU - Hamm, Sebastian Rask
AU - Møller, Dina Leth
AU - Pries-Heje, Mia
AU - Fogh, Kamille
AU - Gerstoft, Jan
AU - Grønbæk, Kirsten
AU - Ostrowski, Sisse Rye
AU - Frikke-Schmidt, Ruth
AU - Sørensen, Erik
AU - Hilsted, Linda
AU - Bundgaard, Henning
AU - Garred, Peter
AU - Iversen, Kasper
AU - Sabin, Caroline
AU - Nielsen, Susanne Dam
N1 - Publisher Copyright: © 2023
PY - 2023
Y1 - 2023
N2 - Background: We investigated long-term durability of humoral and cellular immune responses to third dose of BNT162b2 in people with HIV (PWH) and controls. Methods: In 378 PWH with undetectable viral replication and 224 matched controls vaccinated with three doses of BNT162b2, we measured IgG-antibodies against the receptor binding domain of SARS-CoV-2 spike protein three months before third dose of BNT162b2, and four and eleven months after. In 178 PWH and 135 controls, the cellular response was assessed by interferon-γ (IFN-γ) release in whole blood four months after third dose. Differences in antibody or IFN-γ concentrations were assessed by uni- and multivariable linear regressions. Findings: Before the third dose the concentration of SARS-CoV-2 antibodies was lower in PWH than in controls (unadjusted geometric mean ratio (GMR): 0.68 (95% CI: 0.54–0.86, p = 0.002). We observed no differences in antibody concentrations between PWH and controls after four (0.90 (95% CI: 0.75–1.09), p = 0.285) or eleven months (0.89 (95% CI: 0.69–1.14), p = 0.346) after the third dose. We found no difference in IFN-γ concentrations four months after the third dose between PWH and controls (1.06 (95% CI: 0.71–1.60), p = 0.767). Interpretation: We found no differences in antibody concentrations or cellular response between PWH and controls up to eleven months after third dose of BNT162b2. Our findings indicate that PWH with undetectable viral replication and controls have comparable immune responses to three doses of the BNT162b2 vaccine. Funding: This work was funded by the Novo Nordisk Foundation (NFF205A0063505, NNF20SA0064201), the Carlsberg Foundation (CF20-476 0045), the Svend Andersen Research Foundation (SARF2021), and Bio- and Genome Bank Denmark.
AB - Background: We investigated long-term durability of humoral and cellular immune responses to third dose of BNT162b2 in people with HIV (PWH) and controls. Methods: In 378 PWH with undetectable viral replication and 224 matched controls vaccinated with three doses of BNT162b2, we measured IgG-antibodies against the receptor binding domain of SARS-CoV-2 spike protein three months before third dose of BNT162b2, and four and eleven months after. In 178 PWH and 135 controls, the cellular response was assessed by interferon-γ (IFN-γ) release in whole blood four months after third dose. Differences in antibody or IFN-γ concentrations were assessed by uni- and multivariable linear regressions. Findings: Before the third dose the concentration of SARS-CoV-2 antibodies was lower in PWH than in controls (unadjusted geometric mean ratio (GMR): 0.68 (95% CI: 0.54–0.86, p = 0.002). We observed no differences in antibody concentrations between PWH and controls after four (0.90 (95% CI: 0.75–1.09), p = 0.285) or eleven months (0.89 (95% CI: 0.69–1.14), p = 0.346) after the third dose. We found no difference in IFN-γ concentrations four months after the third dose between PWH and controls (1.06 (95% CI: 0.71–1.60), p = 0.767). Interpretation: We found no differences in antibody concentrations or cellular response between PWH and controls up to eleven months after third dose of BNT162b2. Our findings indicate that PWH with undetectable viral replication and controls have comparable immune responses to three doses of the BNT162b2 vaccine. Funding: This work was funded by the Novo Nordisk Foundation (NFF205A0063505, NNF20SA0064201), the Carlsberg Foundation (CF20-476 0045), the Svend Andersen Research Foundation (SARF2021), and Bio- and Genome Bank Denmark.
KW - BNT162b2
KW - Booster dose
KW - HIV
KW - Immune response
KW - SARS-CoV-2
U2 - 10.1016/j.ebiom.2023.104661
DO - 10.1016/j.ebiom.2023.104661
M3 - Journal article
C2 - 37331161
AN - SCOPUS:85162027082
VL - 93
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
M1 - 104661
ER -
ID: 360403389